Nu Skin Enterprises, Inc. (NUS) Financial Ratios
30 years of historical data (1996–2025) · Consumer Defensive · Household & Personal Products
EV/EBITDA
↓
2.58
↓-72% vs avg
5yr avg: 9.06
30Y Low3.7·High18.3
P/FCF
↓
5.30
↓-76% vs avg
5yr avg: 22.15
30Y Low4.9·High43.5
P/B Ratio
↓
0.31
↓-79% vs avg
5yr avg: 1.51
30Y Low0.5·High23.8
ROE
↑
22.0%
↓+255% vs avg
5yr avg: 6.2%
30Y Low-20%·High96%
Debt/EBITDA
↑
2.54
↓-15% vs avg
5yr avg: 2.99
30Y Low0.1·High5.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NUS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Nu Skin Enterprises, Inc. trades at 1.6x earnings, 96% below its 5-year average of 38.8x, sitting at the 0th percentile of its historical range. Compared to the Consumer Defensive sector median P/E of 18.8x, the stock trades at a discount of 92%. On a free-cash-flow basis, the stock trades at 5.3x P/FCF, 76% below the 5-year average of 22.1x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $244M | $484M | $342M | $968M | $2.1B | $2.6B | $2.9B | $2.3B | $3.5B | $3.7B | $2.7B |
| Enterprise Value | $369M | $610M | $634M | $1.3B | $2.4B | $2.8B | $3.0B | $2.5B | $3.5B | $3.7B | $2.7B |
| P/E Ratio → | 1.58 | 3.03 | — | 114.24 | 20.37 | 17.74 | 15.05 | 13.22 | 28.39 | 28.91 | 18.74 |
| P/S Ratio | 0.16 | 0.33 | 0.20 | 0.49 | 0.96 | 0.97 | 1.12 | 0.95 | 1.29 | 1.64 | 1.21 |
| P/B Ratio | 0.31 | 0.60 | 0.53 | 1.18 | 2.37 | 2.86 | 3.22 | 2.62 | 4.43 | 5.31 | 4.04 |
| P/FCF | 5.30 | 10.52 | 4.88 | 16.10 | 43.47 | 35.77 | 9.14 | 20.49 | 26.17 | 15.44 | 11.91 |
| P/OCF | 3.04 | 6.03 | 3.06 | 8.16 | 19.71 | 18.43 | 7.60 | 12.88 | 17.08 | 12.37 | 9.74 |
P/E links to full P/E history page with 30-year chart
NUS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Nu Skin Enterprises, Inc.'s enterprise value stands at 2.6x EBITDA, 72% below its 5-year average of 9.1x. The Consumer Defensive sector median is 11.0x, placing the stock at a 77% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.41 | 0.37 | 0.67 | 1.07 | 1.03 | 1.15 | 1.02 | 1.31 | 1.63 | 1.24 |
| EV / EBITDA | 2.58 | 4.26 | — | 11.23 | 13.01 | 7.73 | 8.99 | 7.16 | 10.83 | 10.71 | 9.03 |
| EV / EBIT | 4.06 | 6.71 | — | 9.87 | 23.29 | 11.39 | 11.57 | 9.21 | 11.26 | 13.50 | 11.86 |
| EV / FCF | — | 13.25 | 9.03 | 21.94 | 48.69 | 38.02 | 9.45 | 22.02 | 26.50 | 15.28 | 12.18 |
NUS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Nu Skin Enterprises, Inc. earns an operating margin of 6.1%, above the Consumer Defensive sector average of 3.5%. Operating margins have expanded from 2.5% to 6.1% over the past 3 years, signaling improving operational efficiency. ROE of 22.0% indicates solid capital efficiency, compared to the sector median of 6.5%. ROIC of 7.3% represents adequate returns on invested capital versus a sector median of 5.7%.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.4% | 69.4% | 68.2% | 68.9% | 71.7% | 75.0% | 74.5% | 76.0% | 76.3% | 78.0% | 77.3% |
| Operating Margin | 6.1% | 6.1% | -8.8% | 2.5% | 5.0% | 8.7% | 10.0% | 11.0% | 9.0% | 12.0% | 10.5% |
| Net Profit Margin | 10.8% | 10.8% | -8.5% | 0.4% | 4.7% | 5.5% | 7.4% | 7.2% | 4.5% | 5.7% | 6.5% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 22.0% | 22.0% | -19.9% | 1.0% | 11.6% | 16.3% | 21.6% | 20.9% | 16.4% | 18.9% | 19.2% |
| ROA | 11.1% | 11.1% | -9.0% | 0.5% | 5.6% | 7.6% | 10.3% | 10.0% | 7.4% | 8.4% | 9.6% |
| ROIC | 7.3% | 7.3% | -10.7% | 3.1% | 7.5% | 17.0% | 19.0% | 21.4% | 24.2% | 29.6% | 23.0% |
| ROCE | 7.9% | 7.9% | -11.4% | 3.3% | 7.8% | 16.8% | 18.2% | 20.1% | 20.1% | 24.8% | 21.3% |
NUS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Nu Skin Enterprises, Inc. carries a Debt/EBITDA ratio of 2.5x, which is moderately leveraged (27% below the sector average of 3.5x). Net debt stands at $126M ($364M total debt minus $239M cash). Interest coverage of 6.5x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.45 | 0.45 | 0.73 | 0.74 | 0.58 | 0.55 | 0.56 | 0.58 | 0.55 | 0.55 | 0.63 |
| Debt / EBITDA | 2.54 | 2.54 | — | 5.17 | 2.84 | 1.40 | 1.51 | 1.47 | 1.33 | 1.12 | 1.37 |
| Net Debt / Equity | — | 0.16 | 0.45 | 0.43 | 0.29 | 0.18 | 0.11 | 0.20 | 0.06 | -0.05 | 0.09 |
| Net Debt / EBITDA | 0.88 | 0.88 | — | 2.99 | 1.40 | 0.46 | 0.29 | 0.50 | 0.13 | -0.11 | 0.20 |
| Debt / FCF | — | 2.73 | 4.15 | 5.84 | 5.22 | 2.25 | 0.31 | 1.53 | 0.33 | -0.16 | 0.27 |
| Interest Coverage | 6.52 | 6.52 | -5.63 | 5.23 | 4.68 | 22.13 | 19.66 | 13.93 | — | — | — |
NUS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Nu Skin Enterprises, Inc.'s current ratio of 2.08x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 1.40x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 2.13x to 2.08x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.08 | 2.08 | 1.82 | 2.13 | 2.12 | 1.65 | 1.66 | 2.07 | 1.82 | 1.74 | 1.79 |
| Quick Ratio | 1.40 | 1.40 | 1.17 | 1.28 | 1.15 | 0.89 | 1.08 | 1.30 | 1.15 | 1.17 | 1.16 |
| Cash Ratio | 0.91 | 0.91 | 0.67 | 0.81 | 0.78 | 0.67 | 0.78 | 0.96 | 0.91 | 0.98 | 0.92 |
| Asset Turnover | — | 1.06 | 1.18 | 1.09 | 1.22 | 1.41 | 1.32 | 1.37 | 1.58 | 1.43 | 1.50 |
| Inventory Turnover | 2.54 | 2.54 | 2.89 | 2.19 | 1.82 | 1.69 | 2.09 | 2.11 | 2.14 | 1.98 | 2.00 |
| Days Sales Outstanding | — | 9.72 | 10.70 | 13.51 | 7.77 | 5.59 | 8.96 | 7.60 | 7.26 | 5.32 | 5.16 |
NUS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Nu Skin Enterprises, Inc. returns 12.9% to shareholders annually — split between a 4.7% dividend yield and 8.2% buyback yield. The payout ratio of 7.4% is conservative, leaving significant room for dividend growth or reinvestment. The earnings yield of 63.3% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 4.7% | 2.4% | 3.5% | 8.0% | 3.6% | 2.9% | 2.7% | 3.6% | 2.3% | 2.0% | 2.9% |
| Payout Ratio | 7.4% | 7.4% | — | 903.1% | 73.5% | 51.8% | 41.0% | 47.4% | 66.1% | 58.8% | 54.8% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 63.3% | 33.1% | — | 0.9% | 4.9% | 5.6% | 6.6% | 7.6% | 3.5% | 3.5% | 5.3% |
| FCF Yield | 18.9% | 9.5% | 20.5% | 6.2% | 2.3% | 2.8% | 10.9% | 4.9% | 3.8% | 6.5% | 8.4% |
| Buyback Yield | 8.2% | 4.1% | 0.6% | 1.3% | 3.3% | 3.1% | 5.0% | 0.0% | 2.0% | 1.9% | 9.2% |
| Total Shareholder Yield | 12.9% | 6.6% | 4.1% | 9.4% | 6.9% | 6.0% | 7.7% | 3.6% | 4.3% | 3.9% | 12.1% |
| Shares Outstanding | — | $50M | $50M | $50M | $51M | $51M | $53M | $56M | $56M | $55M | $56M |
Peer Comparison
Compare NUS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NUSYou | $244M | 1.6 | 2.6 | 5.3 | 69.4% | 6.1% | 22.0% | 7.3% | 2.5 |
 HLF | $1B | 5.4 | 5.7 | 4.9 | 75.6% | 8.8% | — | 24.3% | 4.2 |
 USNA | $348M | 32.6 | 2.3 | 40.9 | 78.3% | 5.5% | 1.8% | 8.6% | 0.2 |
 NATR | $354M | 19.0 | 7.2 | 12.3 | 72.4% | 5.2% | 12.1% | 21.0% | 0.5 |
 MED | $123M | -6.5 | — | 98.3 | 71.3% | -3.7% | -9.1% | -8.1% | — |
 EL | $31B | -26.9 | 20.8 | 45.7 | 73.9% | 6.7% | -24.7% | 6.5% | 5.3 |
 COTY | $2B | -4.4 | 8.6 | 6.2 | 64.8% | 4.1% | -9.0% | 2.3% | 6.4 |
 IPAR | $3B | 18.9 | 11.9 | 16.7 | 63.6% | 18.2% | 16.5% | 18.6% | 0.8 |
 ELF | $4B | 145.9 | 21.1 | 20.1 | 70.7% | 8.0% | 5.8% | 7.3% | 4.4 |
 SKIN | $86M | -4.1 | 51.0 | 2.3 | 65.3% | -6.9% | -16.9% | -6.8% | 83.3 |
 AMZN | $2.6T | 34.1 | 18.5 | 341.6 | 50.3% | 11.2% | 22.3% | 14.7% | 1.0 |
| Consumer Defensive Median | — | 18.8 | 11.0 | 15.3 | 40.8% | 3.5% | 6.5% | 5.7% | 3.5 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
NUS — Frequently Asked Questions
Quick answers to the most common questions about buying NUS stock.
What is Nu Skin Enterprises, Inc.'s P/E ratio?
Nu Skin Enterprises, Inc.'s current P/E ratio is 1.6x. The historical average is 21.5x.
What is Nu Skin Enterprises, Inc.'s EV/EBITDA?
Nu Skin Enterprises, Inc.'s current EV/EBITDA is 2.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 9.2x.
What is Nu Skin Enterprises, Inc.'s ROE?
Nu Skin Enterprises, Inc.'s return on equity (ROE) is 22.0%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 24.8%.
Is NUS stock overvalued?
Based on historical data, Nu Skin Enterprises, Inc. is trading at a P/E of 1.6x. Compare with industry peers and growth rates for a complete picture.
What is Nu Skin Enterprises, Inc.'s dividend yield?
Nu Skin Enterprises, Inc.'s current dividend yield is 4.69% with a payout ratio of 7.4%.
What are Nu Skin Enterprises, Inc.'s profit margins?
Nu Skin Enterprises, Inc. has 69.4% gross margin and 6.1% operating margin.
How much debt does Nu Skin Enterprises, Inc. have?
Nu Skin Enterprises, Inc.'s Debt/EBITDA ratio is 2.5x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.